Nephros (NEPH) Competitors $1.57 -0.03 (-1.63%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEPH vs. APT, CTSO, WOK, APYX, DHAI, TMDIF, ICAD, INO, LUCD, and NTRBShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Alpha Pro Tech (APT), Cytosorbents (CTSO), WORK Medical Technology Group LTD Ordinary Shares (WOK), Apyx Medical (APYX), DIH Holding US (DHAI), Titan Medical (TMDIF), iCAD (ICAD), Inovio Pharmaceuticals (INO), Lucid Diagnostics (LUCD), and Nutriband (NTRB). These companies are all part of the "medical equipment" industry. Nephros vs. Alpha Pro Tech Cytosorbents WORK Medical Technology Group LTD Ordinary Shares Apyx Medical DIH Holding US Titan Medical iCAD Inovio Pharmaceuticals Lucid Diagnostics Nutriband Nephros (NASDAQ:NEPH) and Alpha Pro Tech (NYSE:APT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Which has stronger valuation and earnings, NEPH or APT? Alpha Pro Tech has higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.24M1.17-$1.58M-$0.09-17.49Alpha Pro Tech$61.23M0.99$4.19M$0.3714.92 Do insiders & institutionals have more ownership in NEPH or APT? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 14.0% of Alpha Pro Tech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate NEPH or APT? Nephros presently has a consensus target price of $5.00, suggesting a potential upside of 217.66%. Given Nephros' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nephros is more favorable than Alpha Pro Tech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NEPH or APT more profitable? Alpha Pro Tech has a net margin of 6.99% compared to Nephros' net margin of -6.86%. Alpha Pro Tech's return on equity of 6.70% beat Nephros' return on equity.Company Net Margins Return on Equity Return on Assets Nephros-6.86% -11.39% -8.30% Alpha Pro Tech 6.99%6.70%5.76% Does the media refer more to NEPH or APT? In the previous week, Nephros' average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score. Company Overall Sentiment Nephros Neutral Alpha Pro Tech Neutral Does the MarketBeat Community prefer NEPH or APT? Alpha Pro Tech received 6 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 100.00% of users gave Alpha Pro Tech an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformNephrosOutperform Votes1343.33% Underperform Votes1756.67% Alpha Pro TechOutperform Votes19100.00% Underperform VotesNo Votes Which has more volatility and risk, NEPH or APT? Nephros has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Alpha Pro Tech has a beta of -0.71, suggesting that its share price is 171% less volatile than the S&P 500. SummaryAlpha Pro Tech beats Nephros on 10 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.59M$4.83B$5.39B$9.13BDividend YieldN/A52.58%5.37%4.00%P/E Ratio-17.4926.8888.8317.53Price / Sales1.1758.531,284.8380.47Price / CashN/A50.8936.6032.90Price / Book1.977.904.964.69Net Income-$1.58M$13.87M$117.89M$224.57M7 Day Performance4.93%4.15%2.74%3.33%1 Month Performance2.21%11.37%3.63%5.33%1 Year Performance-54.44%33.39%27.26%22.97% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.6633 of 5 stars$1.57-1.6%$5.00+217.7%-53.7%$16.59M$14.24M-17.4930High Trading VolumeAPTAlpha Pro TechN/A$5.71-1.0%N/A+9.8%$62.80M$59.29M15.43120CTSOCytosorbents2.3734 of 5 stars$1.11+18.3%$4.67+320.5%+7.3%$60.68M$33.79M-3.08220Analyst ForecastWOKWORK Medical Technology Group LTD Ordinary SharesN/A$4.16-3.7%N/AN/A$60.32M$9.86M0.00226Positive NewsAPYXApyx Medical1.121 of 5 stars$1.51-5.0%N/A-30.2%$56.84M$48.54M-1.82270Gap UpDHAIDIH Holding USN/A$1.35-6.8%N/AN/A$54.80M$64.47M0.00N/ATMDIFTitan MedicalN/A$0.47-5.3%N/A+639.8%$53.98M$17.63M-0.3850Gap DownICADiCAD1.1986 of 5 stars$1.90flatN/A+27.6%$50.43M$18.94M-14.62140News CoverageGap DownINOInovio Pharmaceuticals4.2207 of 5 stars$1.92-3.0%$12.40+545.8%-97.9%$50.11M$203,413.00-0.92320LUCDLucid Diagnostics2.3845 of 5 stars$0.81-2.9%$3.63+345.4%-41.9%$48.29M$4.19M-0.7170News CoverageNTRBNutriband0.2561 of 5 stars$4.25+2.9%N/A+55.4%$47.20M$2.02M-5.9910Gap Down Related Companies and Tools Related Companies Alpha Pro Tech Competitors Cytosorbents Competitors WORK Medical Technology Group LTD Ordinary Shares Competitors Apyx Medical Competitors DIH Holding US Competitors Titan Medical Competitors iCAD Competitors Inovio Pharmaceuticals Competitors Lucid Diagnostics Competitors Nutriband Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEPH) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
